AUSTEDO: Demonstrated safety and tolerability profile in Huntington’s disease (HD) chorea patients1

Rates of discontinuation and dose reduction due to adverse events were similar across study arms1,2

  • Discontinuation due to adverse events occurred in 2% of patients in both the AUSTEDO and placebo arms
  • Dose reduction due to adverse events was required in 7% of patients in both the AUSTEDO and placebo arms

Adverse Events Reported in ≥4% of Patients Treated With AUSTEDO in the Placebo-controlled Study1,3

Adverse events reported in ≥4% of patients treated with AUSTEDO in the placebo controlled study. Adverse events reported in ≥4% of patients treated with AUSTEDO in the placebo controlled study.

Adverse events not reported once patients reached their maintenance dose were3:

  • Somnolence
  • Diarrhea
  • Dry mouth
  • Fatigue
  • Adverse events of special interest, including parkinsonism, akathisia, restlessness, and suicidal ideation, were not reported in any patients during titration phase and were reported in ≤4% of patients in both arms during maintenance phase2
  • Anxiety was reported in ≤4% of patients in both arms during titration and maintenance phases3

REFERENCES: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 2. Frank S, Testa CM, Stamler D, et al.; Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40-50. 3. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.